Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study

Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment. To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, pl...

Full description

Saved in:
Bibliographic Details
Published in:British journal of psychiatry 2001-07, Vol.179 (1), p.15-22
Main Authors: ALLGULANDER, CHRISTER, HACKETT, DAVID, SALINAS, ELISEO
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antidepressants
Antidepressive Agents, Second-Generation - administration & dosage
Anxiety
Anxiety disorders
Anxiety Disorders - drug therapy
Chronic Disease
College professors
Comorbidity
Cyclohexanols - administration & dosage
Delayed-Action Preparations
Discontinued
Dosage
Double-Blind Method
Double-blind studies
Efficacy
Family physicians
Female
Generalized anxiety disorder
Humans
Male
Mental depression
Middle Aged
Psychiatric Status Rating Scales
Psychiatry
Release
Venlafaxine
Venlafaxine Hydrochloride
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment. To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER. All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups. Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.
ISSN:0007-1250
1472-1465
DOI:10.1192/bjp.179.1.15